In addition, novel targets are under investigation example, CDK1 has been identified as a key regulator of GIST growth and proliferation, suggesting that CDK1 inhibitors could be potential therapeutic agents [69]. This evidence concerns the gene CDK1 and gastrointestinal stromal tumor.